Chemical formula: C₈H₁₇NO₂ Molecular mass: 159.226 g/mol PubChem compound: 5486971
Pregabalin interacts in the following cases:
Caution is advised when prescribing pregabalin concomitantly with opioids due to risk of CNS depression. In a case-control study of opioid users, those patients who took pregabalin concomitantly with an opioid had an increased risk for opioid-related death compared to opioid use alone (adjusted odds ratio [aOR], 1.68 [95% CI, 1.19–2.36]). This increased risk was observed at low doses of pregabalin (≤300 mg, aOR 1.52 [95% CI, 1.04–2.22]) and there was a trend for a greater risk at high doses of pregabalin (>300 mg, aOR 2.51 [95% CI 1.24–5.06]).
There are postmarketing reports of events related to reduced lower gastrointestinal tract function (e.g. intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation, such as opioid analgesics. When pregabalin and opioids will be used in combination, measures to prevent constipation may be considered (especially in female patients and elderly).
Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug.
As pregabalin clearance is directly proportional to creatinine clearance, dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CLcr), as indicated in Table 1 determined using the following formula:
CLcr = [1.23 X [140 - age (years)] X weight (kg) / serum creatinine (μmol/l)] (X 0.85 for female patients)
Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4 hour haemodialysis treatment (see Table 1).
Table 1. Pregabalin Dose Adjustment Based on Renal Function:
| Creatinine clearance (CLcr) (ml/min) | Total pregabalin daily dose* | Dose regimen | |
| Starting dose (mg/day) | Maximum dose (mg/day) | ||
| ≥60 | 150 | 600 | BID or TID |
| ≥30 - <60 | 75 | 300 | BID or TID |
| ≥15 - <30 | 25–50 | 150 | Once Daily or BID |
| <15 | 25 | 75 | Once Daily |
| Supplementary dosage following haemodialysis (mg) | |||
| 25 | 100 | Single dose+ | |
TID = Three divided doses
BID = Two divided doses
* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose
+ Supplementary dose is a single additional dose
Pregabalin may potentiate the effects of ethanol and lorazepam.
In the postmarketing experience, there are reports of respiratory failure, coma and deaths in patients taking pregabalin and opioids and/or other central nervous system (CNS) depressant medicinal products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.
There are no clinical data on the effects of pregabalin on female fertility.
In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no effects on sperm motility.
A fertility study in female rats has shown adverse reproductive effects. Fertility studies in male rats have shown adverse reproductive and developmental effects. The clinical relevance of these findings is unknown.
Pregabalin can cause drug dependence, which may occur at therapeutic doses. Cases of abuse and misuse have been reported. Patients with a history of substance abuse may be at higher risk for pregabalin misuse, abuse and dependence, and pregabalin should be used with caution in such patients. Before prescribing pregabalin, the patient's risk of misuse, abuse or dependence should be carefully evaluated.
There have been postmarketing reports of congestive heart failure in some patients receiving pregabalin. These reactions are mostly seen in elderly cardiovascular compromised patients during pregabalin treatment for a neuropathic indication. Pregabalin should be used with caution in these patients. Discontinuation of pregabalin may resolve the reaction.
In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medicinal products.
Studies in animals have shown reproductive toxicity.
Pregabalin has been shown to cross the placenta in rats. Pregabalin may cross the human placenta.
Data from a Nordic observational study of more than 2700 pregnancies exposed to pregabalin in the first trimester showed a higher prevalence of major congenital malformations (MCM) among the paediatric population (live or stillborn) exposed to pregabalin compared to the unexposed population (5.9% vs. 4.1%).
The risk of MCM among the paediatric population exposed to pregabalin in the first trimester was slightly higher compared to unexposed population (adjusted prevalence ratio and 95% confidence interval: 1.14 (0.96-1.35)), and compared to population exposed to lamotrigine (1.29 (1.01–1.65)) or to duloxetine (1.39 (1.07–1.82)).
The analyses on specific malformations showed higher risks for malformations of the nervous system, the eye, orofacial clefts, urinary malformations and genital malformations, but numbers were small and estimates imprecise.
Pregabalin should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus).
Pregabalin is excreted into human milk. The effect of pregabalin on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Women of childbearing potential have to use effective contraception during treatment.
There are no clinical data on the effects of pregabalin on female fertility.
In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no effects on sperm motility.
A fertility study in female rats has shown adverse reproductive effects. Fertility studies in male rats have shown adverse reproductive and developmental effects. The clinical relevance of these findings is unknown.
Pregabalin may have minor or moderate influence on the ability to drive and use machines. Pregabalin may cause dizziness and somnolence and therefore may influence the ability to drive or use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.
The pregabalin clinical programme involved over 8,900 patients exposed to pregabalin, of whom over 5,600 were in double-blind placebo controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.
In the table below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products.
In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased.
Additional reactions reported from postmarketing experience are included in italics in the list below.
Pregabalin Adverse Drug Reactions:
| System Organ Class | Adverse drug reactions |
| Infections and infestations | |
| Common | Nasopharyngitis |
| Blood and lymphatic system disorders | |
| Uncommon | Neutropaenia |
| Immune system disorders | |
| Uncommon | Hypersensitivity |
| Rare | Angioedema, allergic reaction |
| Metabolism and nutrition disorders | |
| Common | Appetite increased |
| Uncommon | Anorexia, hypoglycaemia |
| Psychiatric disorders | |
| Common | Euphoric mood, confusion, irritability, disorientation, insomnia,libido decreased |
| Uncommon | Hallucination, panic attack, restlessness, agitation, depression, depressed mood, elevated mood, aggression, mood swings, depersonalisation, word finding difficulty, abnormal dreams, libido increased, anorgasmia, apathy |
| Rare | Disinhibition, suicidal behaviour, suicidal ideation |
| Not known | Drug dependence |
| Nervous system disorders | |
| Very Common | Dizziness, somnolence, headache |
| Common | Ataxia, coordination abnormal, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy |
| Uncommon | Syncope, stupor, myoclonus, loss of consciousness, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, cognitive disorder, mental impairment, speech disorder, hyporeflexia, hyperaesthesia, burning sensation, ageusia, malaise |
| Rare | Convulsions, parosmia, hypokinesia, dysgraphia, parkinsonism |
| Eye disorders | |
| Common | Vision blurred, diplopia |
| Uncommon | Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, dry eye, lacrimation increased, eye irritation |
| Rare | Vision loss, keratitis, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness |
| Ear and labyrinth disorders | |
| Common | Vertigo |
| Uncommon | Hyperacusis |
| Cardiac disorders | |
| Uncommon | Tachycardia, atrioventricular block first degree, sinus bradycardia, congestive heart failure |
| Rare | QT prolongation, sinus tachycardia, sinus arrhythmia |
| Vascular disorders | |
| Uncommon | Hypotension, hypertension, hot flushes, flushing, peripheral coldness |
| Respiratory, thoracic and mediastinal disorders | |
| Uncommon | Dyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness |
| Rare | Pulmonary oedema, throat tightness |
| Not known | Respiratory depression |
| Gastrointestinal disorders | |
| Common | Vomiting, nausea, constipation, diarrhoea, flatulence, abdominal distension, dry mouth |
| Uncommon | Gastrooesophageal reflux disease, salivary hypersecretion, hypoaesthesia oral |
| Rare | Ascites, pancreatitis, swollen tongue, dysphagia |
| Hepatobiliary disorders | |
| Uncommon | Elevated liver enzymes* |
| Rare | Jaundice |
| Very rare | Hepatic failure, hepatitis |
| Skin and subcutaneous tissue disorders | |
| Uncommon | Rash papular, urticaria, hyperhidrosis, pruritus |
| Rare | Toxic epidermal necrolysis, Stevens-Johnson syndrome, cold sweat |
| Musculoskeletal and connective tissue disorders | |
| Common | Muscle cramp, arthralgia, back pain, pain in limb, cervical spasm |
| Uncommon | Joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness |
| Rare | Rhabdomyolysis |
| Renal and urinary disorders | |
| Uncommon | Urinary incontinence, dysuria |
| Rare | Renal failure, oliguria, urinary retention |
| Reproductive system and breast disorders | |
| Common | Erectile dysfunction |
| Uncommon | Sexual dysfunction, ejaculation delayed, dysmenorrhoea, breast pain |
| Rare | Amenorrhoea, breast discharge, breast enlargement, gynaecomastia |
| General disorders and administration site conditions | |
| Common | Oedema peripheral, oedema, gait abnormal, fall, feeling drunk, feeling abnormal, fatigue |
| Uncommon | Generalised oedema, face oedema, chest tightness, pain, pyrexia, thirst, chills, asthenia |
| Investigations | |
| Common | Weight increased |
| Uncommon | Blood creatine phosphokinase increased, blood glucose increased, platelet count decreased, blood creatinine increased, blood potassium decreased, weight decreased |
| Rare | White blood cell count decreased |
* Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST).
After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed. The following symptoms have been reported: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, suicidal ideation, pain, hyperhidrosis and dizziness. These symptoms may indicate drug dependence. The patient should be informed about this at the start of the treatment. Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.
The pregabalin safety profile observed in five paediatric studies in patients with partial seizures with or without secondary generalisation (12-week efficacy and safety study in patients 4 to 16 years of age, n=295; 14-day efficacy and safety study in patients 1 month to younger than 4 years of age, n=175; pharmacokinetic and tolerability study, n=65; and two 1 year open label follow on safety studies, n=54 and n=431) was similar to that observed in the adult studies of patients with epilepsy. The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis. The most common adverse events observed in the 14-day study with pregabalin treatment were somnolence, upper respiratory tract infection, and pyrexia.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.